Physician profile
Chuan Jiang
NPI 1790028025
$11,439.50
in general payments reported to CMS, 2019-2025
36 companies · $3,065 in 2025
The $3,065 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $155 · 2021: $1,277 · 2022: $1,571 · 2023: $2,632 · 2024: $2,740 · 2025: $3,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,433 · Education: $2.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,433.36 |
| Education | $2.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,656.41 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,232.73 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $957.24 | 2020-2025 | Jardiance, Ofev, Spiriva Respimat |
| Lilly USA, LLC | $664.80 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Ardelyx, INC. | $559.87 | 2023-2025 | Ibsrela |
| Abbvie INC. | $456.20 | 2022-2025 | |
| Amarin Pharma, INC. | $446.38 | 2021-2023 | |
| Electromed, INC. | $444.02 | 2023-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $417.16 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $413.89 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $408.45 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Genzyme Corporation | $327.78 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $303.74 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $270.87 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $232.13 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $231.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $193.43 | 2022 | |
| Amgen INC. | $184.51 | 2020-2025 | Tezspire, Evenity, Prolia |
| Insmed, INC. | $119.20 | 2023-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $106.23 | 2023-2025 | Opsumit |
| Mylan Specialty L.P. | $97.47 | 2023-2024 | Yupelri |
| Madrigal Pharmaceuticals | $94.43 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $88.24 | 2021-2025 | Nexletol |
| Philips North America LLC | $67.04 | 2020-2025 | Vest Therapy Und |
| Exact Sciences Corporation | $61.94 | 2024-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $58.69 | 2025 | Zenpep |
| Baxter Healthcare | $56.86 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $48.45 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $46.84 | 2022-2023 | Prehevbrio |
| Pfizer INC. | $45.86 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $38.08 | 2023 | Quviviq |
| Intra-Sana Laboratories | $24.72 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Radius Health, INC. | $22.85 | 2021 | |
| Ibsa Pharma INC. | $22.27 | 2021 | |
| Phadia US INC. | $20.67 | 2023 | Immunocap |
| Opko Pharmaceuticals, LLC | $18.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chuan Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.